Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, announced its participation in the 2025 Wells Fargo Healthcare Conference. The company's executive team will be available for one-on-one meetings during the conference, which takes place from September 3-5, 2025 in Boston, MA.
Interested parties can schedule meetings through their Wells Fargo institutional sales representatives.
Eton Pharmaceuticals (Nasdaq: ETON), azienda farmaceutica specializzata in terapie per malattie rare, ha annunciato la propria partecipazione alla 2025 Wells Fargo Healthcare Conference. Il team dirigenziale sarà disponibile per incontri individuali durante la conferenza, che si svolgerà dal 3 al 5 settembre 2025 a Boston, MA.
Gli interessati possono fissare gli incontri tramite i loro rappresentanti istituzionali di vendita Wells Fargo.
Eton Pharmaceuticals (Nasdaq: ETON), compañía farmacéutica especializada en tratamientos para enfermedades raras, anunció su participación en la Wells Fargo Healthcare Conference 2025. El equipo ejecutivo estará disponible para reuniones individuales durante la conferencia, que se celebrará del 3 al 5 de septiembre de 2025 en Boston, MA.
Los interesados pueden programar reuniones a través de sus representantes de ventas institucionales de Wells Fargo.
Eton Pharmaceuticals (Nasdaq: ETON), 희귀질환 치료제 전문 제약회사, 2025 Wells Fargo Healthcare Conference 참가를 발표했습니다. 회사 경영진은 2025년 9월 3일~5일 매사추세츠주 보스턴에서 열리는 컨퍼런스 기간 동안 일대일 미팅에 응할 예정입니다.
미팅 예약은 Wells Fargo의 기관 영업 담당자를 통해 진행할 수 있습니다.
Eton Pharmaceuticals (Nasdaq: ETON), société pharmaceutique spécialisée dans les traitements des maladies rares, a annoncé sa participation à la Wells Fargo Healthcare Conference 2025. L'équipe de direction sera disponible pour des entretiens individuels pendant la conférence, qui se tiendra du 3 au 5 septembre 2025 à Boston, MA.
Les personnes intéressées peuvent organiser des réunions via leurs représentants des ventes institutionnelles Wells Fargo.
Eton Pharmaceuticals (Nasdaq: ETON), ein Pharmaunternehmen, das sich auf Therapien für seltene Erkrankungen spezialisiert hat, gab seine Teilnahme an der Wells Fargo Healthcare Conference 2025 bekannt. Das Führungsteam steht während der Konferenz für Einzelgespräche zur Verfügung, die vom 3. bis 5. September 2025 in Boston, MA, stattfindet.
Interessenten können Termine über ihre institutionellen Vertriebsvertreter von Wells Fargo vereinbaren.
- None.
- None.
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.
To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
This press release was published by a CLEAR® Verified individual.
FAQ
When is Eton Pharmaceuticals (ETON) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors meet with Eton Pharmaceuticals (ETON) management at the Wells Fargo conference?
Where is the 2025 Wells Fargo Healthcare Conference being held?
What is Eton Pharmaceuticals' (ETON) business focus?
